AXL mediates resistance to cetuximab therapy.
This study shows that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where AXL was overexpressed, activated, and tightly associated with EGFR expression in cells resistant to cetusimab.
Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion.
It is shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation, which induced defective vascular response in tumor implants leading to reduced tumor growth.
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
This work is the first to show that EphB4 is preferentially induced in colorectal cancer, in contrast to EphEphB2, whereby tumor cells acquire a survival advantage.
Cell Surface Relocalization of the Endoplasmic Reticulum Chaperone and Unfolded Protein Response Regulator GRP78/BiP*
It is reported that ER stress actively promotes GRP78 localization on the cell surface, whereas ectopic expression ofGRP78 is also able to cause cell surface relocation in the absence of ER stress.
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
In this large phase III trial, the efficacy of DaunoXome was comparable to that of ABV and is a safe and effective primary therapy for advanced AIDS-related KS.
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.
The combination of zidovudine and interferon alfa has activity against adult T-cell leukemia-lymphoma, even in patients in whom prior cytotoxic therapy has failed.
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
DaunoXome can be given safely at doses up to 60 mg/m2 every 2 weeks and has significant antitumor activity in patients with AIDS-KS and has an improved pharmacokinetic profile compared with free daunorubicin, and is well tolerated.
Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome.
It is concluded that non-Hodgkin's lymphoma in members of an AIDS risk group is a serious manifestation of AIDS and the AIDS-related complex.
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
The data indicate that biologically active EphB4 functions as a survival factor in breast cancer and is a novel target for therapy.